Nuvelo initiated by Global Crown at overweight

Nuvelo Inc. coverage was initiated by Global Crown Capital analyst Kate Winkler at an overweight rating, citing optimism that its lead candidate, Alfimeprase, being developed with Amgen Inc., could mark a watershed in treatment strategies for acute thrombotic events including heart attack and ischemic stroke. Sunnyvale, Calif.-based Nuvelo also has collaboration and licensing agreements with Dendreon Corp., Kirin Brewery Co. Ltd. and Archemix Corp. Nuvelo shares Monday slipped 16 cents, or 1.85%, to $8.49 on volume of 178,345 shares versus the three-month running average of 236,648.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.